DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 19, 2022, covering events occurring on January 18, 2022. DarioHealth Corp. (DRIO), an emerging growth company incorporated in Delaware, reported the entry into a material definitive agreement and the issuance of an investor presentation.
Key Financial Metrics and Transaction Details
The filing details a Technology Purchase Agreement with Physimax Technologies Ltd. Key financial terms include:
- Total Consideration: Approximately $6.52 million in aggregate value.
- Equity Component: Issuance of up to 256,660 shares of common stock valued at $5,500,000 ($21.35 per share).
- Cash Component: $500,000 cash payment.
- Liabilities Assumed: Approximately $1,020,000.
- Lock-up Provisions: Consideration shares are subject to a tiered lock-up schedule (33.3% for 180 days, 33.3% for 270 days, 33.4% for 360 days).
- Holdback Agreements: Key personnel shares are held back by Physimax, with 50% released at the first anniversary and the remaining 50% at 18 months, contingent on continued employment.
The filing references an investor presentation containing non-GAAP financial measures (revenues, cost of revenues, gross profit) that exclude amortized expenses from technology acquisitions. Specific GAAP financial results for the period are not provided in this text.
Material Changes
The primary material change is the acquisition of assets from Physimax Technologies Ltd. via the Company's wholly owned subsidiary, Labstyle Innovation Ltd. This transaction expands the Company's technology portfolio subject to customary closing conditions, including approval from the Israeli Innovation Authority.
Guidance, Outlook, and Risks
The Company announced an investor conference call on January 19, 2022, to discuss the transaction and financial outlook. The filing highlights the following risks and contingencies:
- Closing Conditions: The transaction is not yet closed and is subject to regulatory approval by the Israeli Innovation Authority.
- Non-GAAP Measures: The Company utilizes non-GAAP measures to evaluate performance, which may not be comparable to peer companies and should not be viewed as a substitute for GAAP measures.
- Shareholder Dilution: The issuance of new shares will increase the total share count, subject to the aforementioned lock-up restrictions.
Investor Verification Checklist
- Verify the final closing date and confirmation of Israeli Innovation Authority approval.
- Review the full Investor Presentation (Exhibit 99.1) for specific non-GAAP to GAAP reconciliations and detailed financial projections.
- Confirm the exact number of shares issued upon closing and the impact on fully diluted share count.
- Monitor the status of the holdback agreements for key Physimax personnel to assess retention risks.